在评估针对艾滋病毒潜伏期的干预措施时,对Morpheus-V5双报告病毒的限制和使用
Kiho Tanaka1, Youry Kim1, Jesslyn Ong1
1Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Journal of virological methods
|August 3, 2025
概括
研究人员使用Morpheus-V5病毒研究CD4+T细胞中的HIV潜伏期. 该工具有助于调查旨在破坏持续性艾滋病毒感染的干预措施,尽管在量化潜在感染细胞方面存在一些局限性.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 人类免疫缺陷病毒 (HIV) 通过在潜伏感染的CD4+T细胞中持续存在,从而建立终身感染.
- 了解和准潜伏的艾滋病毒储存库对于开发一种功能性疗法至关重要.
研究的目的:
- 为了对Morpheus-V5双报告者病毒进行表征,用于研究HIV潜伏时间.
- 评估Morpheus-V5作为一种用于调查针对潜伏HIV的干预措施的工具.
主要方法:
- 感染CD4+T细胞与不同的HIV包膜蛋白质伪型的Morpheus-V5.
- 分析报告者基因表达 (mCherry,NGFR) 以区分生产性和潜伏性感染.
- 用延迟逆转剂进行治疗,并评估细胞对亲细胞亡化合物的敏感性.
主要成果:
- 莫菲乌斯-V5成功感染了休息和激活的CD4+T细胞.
- 感染细胞的NGFR表达得到丰富,但也出现在未感染的细胞中.
- 延迟逆转剂增加了mCherry,并降低了NGFR表达.
- 潜伏和生产性感染的细胞对亡有不同的敏感性.
结论:
- 莫菲斯-V5是研究HIV潜伏期和潜在治疗干预措施的宝贵工具.
- 该模型存在局限性,包括高估潜感染细胞.
- 进一步的研究可以改进Morpheus-V5的使用,以更好地了解艾滋病毒的持续性.
相关概念视频
Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


